Neue Aspekte der primären Radiochemotherapie bei Kopf-Hals-Tumoren. Highlights vom ASCO-Kongress 2011
Standard
Neue Aspekte der primären Radiochemotherapie bei Kopf-Hals-Tumoren. Highlights vom ASCO-Kongress 2011. / Laban, S; Wang, C J; Knecht, R; Tribius, S; Münscher, A.
in: HNO, Jahrgang 60, Nr. 5, 01.05.2012, S. 393-7.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Neue Aspekte der primären Radiochemotherapie bei Kopf-Hals-Tumoren. Highlights vom ASCO-Kongress 2011
AU - Laban, S
AU - Wang, C J
AU - Knecht, R
AU - Tribius, S
AU - Münscher, A
PY - 2012/5/1
Y1 - 2012/5/1
N2 - Primary radiochemotherapy is a treatment option for patients with locally advanced or unresectable head and neck cancer. Compared to conventional radiotherapy, intensity-modulated radiotherapy (IMRT) is associated with fewer long-term toxicities and better quality of life. Whether IMRT improves local control in these patients needs to be further investigated. The risk factors and treatment toxicities must be taken into consideration and discussed with the patients. New approaches combining radiotherapy and biological targets are a treatment option. The implementation of these substances in treatment protocols is increasing. Sensitive and specific prognostic biomarkers for patient identification to optimize treatment selection are important, but reliable parameters are still missing.
AB - Primary radiochemotherapy is a treatment option for patients with locally advanced or unresectable head and neck cancer. Compared to conventional radiotherapy, intensity-modulated radiotherapy (IMRT) is associated with fewer long-term toxicities and better quality of life. Whether IMRT improves local control in these patients needs to be further investigated. The risk factors and treatment toxicities must be taken into consideration and discussed with the patients. New approaches combining radiotherapy and biological targets are a treatment option. The implementation of these substances in treatment protocols is increasing. Sensitive and specific prognostic biomarkers for patient identification to optimize treatment selection are important, but reliable parameters are still missing.
KW - Antineoplastic Agents
KW - Chemoradiotherapy
KW - Germany
KW - Head and Neck Neoplasms
KW - Humans
KW - Radiotherapy, Conformal
U2 - 10.1007/s00106-011-2463-0
DO - 10.1007/s00106-011-2463-0
M3 - SCORING: Zeitschriftenaufsatz
C2 - 22570002
VL - 60
SP - 393
EP - 397
JO - HNO
JF - HNO
SN - 0017-6192
IS - 5
ER -